| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +33,042 | +54% | $0.000000 | 93,983 | 15 Feb 2024 | Direct | F1 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +8,810 | +9.4% | $0.000000 | 102,793 | 15 Feb 2024 | Direct | F2 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +7,840 | +7.6% | $0.000000 | 110,633 | 15 Feb 2024 | Direct | F3 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +9,268 | +8.4% | $0.000000 | 119,901 | 15 Feb 2024 | Direct | F4 |
| holding | ABBV | Common Stock, $0.01 par value | 1,338 | 15 Feb 2024 | By spouse in trust | F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Option (Right to Buy) | Award | $0 | +39,085 | $0.000000 | 39,085 | 15 Feb 2024 | Common Stock | 39,085 | $0.000000 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| F2 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| F3 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| F4 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| F5 | The reporting person disclaims beneficial ownership of all securities held by his spouse. |
| F6 | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,029 on February 15, 2025, 13,028 on February 15, 2026, and 13,028 on February 15, 2027. |